Literature DB >> 11316008

Naphthol-ASBI phosphate as a preferred substrate for tartrate-resistant acid phosphatase isoform 5b.

A J Janckila1, K Takahashi, S Z Sun, L T Yam.   

Abstract

Tartrate-resistant acid phosphatase (TRAP) isoform 5b is a potential serum marker for osteoclastic activity. Biochemical assays for serum TRAP activity with para-nitrophenylphosphate (pNPP) have low specificity for bone because of hydrolysis by unrelated nontype 5 TRAPs of blood cells and by related isoform 5a. Our purpose was to increase the specificity of TRAP assay for osteoclastic activity by using naphthol-ASBI phosphate (N-ASBI-P) as a substrate for serum type 5 TRAP activity and heparin as an inhibitor of isoform 5a. TRAP activity in individual and pooled sera of normal subjects and patients with endstage renal disease (ESRD) and rheumatologic diseases was quantitated using pNPP and N-ASBI-P as substrate at pH 5.5 and 6.1. For some experiments, heparin (23U/ml) was added as a specific inhibitor of isoform 5a activity. Isoforms 5a and 5b were separated from serum pools by cation exchange chromatography and identified by nondenaturing polyacrylamide gel electrophoresis (PAGE). N-ASBI-P was selectively hydrolyzed by TRAP isoform 5b. TRAP assays with pNPP and N-ASBI-P correlated only in ESRD sera, which contained primarily isoform 5b. The two assays did not correlate in normal or rheumatic sera with significant amounts of 5a. Heparin inhibited isoform 5a activity approximately 50% but had little effect on isoform 5b activity. Biochemical assay of serum TRAP activity can be made specific for isoform 5b by using N-ASBI-P and heparin. This method can be adapted to simple microplate biochemical or immunochemical assays. This simplified method for assessment of osteoclastic TRAP 5b activity warrants a detailed investigation in diseases of bone metabolism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11316008     DOI: 10.1359/jbmr.2001.16.4.788

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  22 in total

Review 1.  Acid phosphatases.

Authors:  H Bull; P G Murray; D Thomas; A M Fraser; P N Nelson
Journal:  Mol Pathol       Date:  2002-04

2.  Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions.

Authors:  Feng-Chun Yang; Shi Chen; Alexander G Robling; Xijie Yu; Todd D Nebesio; Jincheng Yan; Trent Morgan; Xiaohong Li; Jin Yuan; Janet Hock; David A Ingram; D Wade Clapp
Journal:  J Clin Invest       Date:  2006-10-19       Impact factor: 14.808

3.  Disruption of claudin-18 diminishes ovariectomy-induced bone loss in mice.

Authors:  Ha-Young Kim; Catrina Alarcon; Sheila Pourteymour; Jon E Wergedal; Subburaman Mohan
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-01-08       Impact factor: 4.310

4.  Biological effects of melatonin on osteoblast/osteoclast cocultures, bone, and quality of life: Implications of a role for MT2 melatonin receptors, MEK1/2, and MEK5 in melatonin-mediated osteoblastogenesis.

Authors:  Sifat Maria; Rebekah M Samsonraj; Fahima Munmun; Jessica Glas; Maria Silvestros; Mary P Kotlarczyk; Ryan Rylands; Amel Dudakovic; Andre J van Wijnen; Larry T Enderby; Holly Lassila; Bala Dodda; Vicki L Davis; Judy Balk; Matt Burow; Bruce A Bunnell; Paula A Witt-Enderby
Journal:  J Pineal Res       Date:  2018-01-17       Impact factor: 13.007

5.  Nanocrystalline spherical hydroxyapatite granules for bone repair: in vitro evaluation with osteoblast-like cells and osteoclasts.

Authors:  A Bernhardt; R Dittrich; A Lode; F Despang; M Gelinsky
Journal:  J Mater Sci Mater Med       Date:  2013-04-28       Impact factor: 3.896

6.  Cyclolinopeptide F, a cyclic peptide from flaxseed inhibited RANKL-induced osteoclastogenesis via downergulation of RANK expression.

Authors:  Toshio Kaneda; Yuki Nakajima; Sae Koshikawa; Alfarius Eko Nugroho; Hiroshi Morita
Journal:  J Nat Med       Date:  2019-03-15       Impact factor: 2.343

7.  Whey Protein Concentrate Hydrolysate Prevents Bone Loss in Ovariectomized Rats.

Authors:  Jonggun Kim; Hyung Kwan Kim; Saehun Kim; Ji-Young Imm; Kwang-Youn Whang
Journal:  J Med Food       Date:  2015-09-14       Impact factor: 2.786

8.  NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism.

Authors:  Antonios O Aliprantis; Yasuyoshi Ueki; Rosalyn Sulyanto; Arnold Park; Kirsten S Sigrist; Sudarshana M Sharma; Michael C Ostrowski; Bjorn R Olsen; Laurie H Glimcher
Journal:  J Clin Invest       Date:  2008-10-09       Impact factor: 14.808

9.  HCO3-/Cl- anion exchanger SLC4A2 is required for proper osteoclast differentiation and function.

Authors:  Jing Wu; Laurie H Glimcher; Antonios O Aliprantis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-29       Impact factor: 11.205

10.  SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss.

Authors:  Tomoyuki Mukai; Shu Ishida; Remi Ishikawa; Teruhito Yoshitaka; Mizuho Kittaka; Richard Gallant; Yi-Ling Lin; Robert Rottapel; Marco Brotto; Ernst J Reichenberger; Yasuyoshi Ueki
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.